Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.97 USD
41.95 M USD
674.98 M USD
44.58 M
About Pacira BioSciences, Inc.
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PCRX is 17.43 USD — it has increased by 1.79% in the past 24 hours. Watch Pacira BioSciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Pacira BioSciences, Inc. stocks are traded under the ticker PCRX.
PCRX stock has risen by 1.31% compared to the previous week, the month change is a −1.56% fall, over the last year Pacira BioSciences, Inc. has showed a −35.16% decrease.
We've gathered analysts' opinions on Pacira BioSciences, Inc. future price: according to them, PCRX price has a max estimate of 39.00 USD and a min estimate of 8.00 USD. Watch PCRX chart and read a more detailed Pacira BioSciences, Inc. stock forecast: see what analysts think of Pacira BioSciences, Inc. and suggest that you do with its stocks.
PCRX reached its all-time high on Feb 25, 2015 with the price of 121.95 USD, and its all-time low was 6.16 USD and was reached on Feb 16, 2011. View more price dynamics on PCRX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PCRX stock is 2.56% volatile and has beta coefficient of 0.98. Track Pacira BioSciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Pacira BioSciences, Inc. there?
Today Pacira BioSciences, Inc. has the market capitalization of 786.33 M, it has increased by 4.03% over the last week.
Yes, you can track Pacira BioSciences, Inc. financials in yearly and quarterly reports right on TradingView.
Pacira BioSciences, Inc. is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
PCRX earnings for the last quarter are 0.79 USD per share, whereas the estimation was 0.70 USD resulting in a 12.14% surprise. The estimated earnings for the next quarter are 0.78 USD per share. See more details about Pacira BioSciences, Inc. earnings.
Pacira BioSciences, Inc. revenue for the last quarter amounts to 168.57 M USD, despite the estimated figure of 169.55 M USD. In the next quarter, revenue is expected to reach 180.39 M USD.
PCRX net income for the last quarter is −143.47 M USD, while the quarter before that showed 18.89 M USD of net income which accounts for −859.64% change. Track more Pacira BioSciences, Inc. financial stats to get the full picture.
No, PCRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 712.00 employees. See our rating of the largest employees — is Pacira BioSciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Pacira BioSciences, Inc. EBITDA is 178.03 M USD, and current EBITDA margin is 24.13%. See more stats in Pacira BioSciences, Inc. financial statements.
Like other stocks, PCRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Pacira BioSciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Pacira BioSciences, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Pacira BioSciences, Inc. stock shows the sell signal. See more of Pacira BioSciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.